|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CCL11 |
 Gene summary |
| Basic gene Info. | Gene symbol | CCL11 |
| Gene name | chemokine (C-C motif) ligand 11 | |
| Synonyms | SCYA11 | |
| Cytomap | UCSC genome browser: 17q12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_002986.2, | |
| Description | eosinophil chemotactic proteineotaxineotaxin-1small inducible cytokine subfamily A (Cys-Cys), member 11 (eotaxin) | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601156 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000172156 | ||
| HPRD : 03098 | ||
| Vega : OTTHUMG00000132884 | ||
| Protein | UniProt: P51671 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CCL11 | |
| BioGPS: 6356 | ||
| Pathway | NCI Pathway Interaction Database: CCL11 | |
| KEGG: CCL11 | ||
| REACTOME: CCL11 | ||
| Pathway Commons: CCL11 | ||
| Context | iHOP: CCL11 | |
| ligand binding site mutation search in PubMed: CCL11 | ||
| UCL Cancer Institute: CCL11 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0001938 | positive regulation of endothelial cell proliferation | 19525930 | GO:0007010 | cytoskeleton organization | 10072545 | GO:0008360 | regulation of cell shape | 10072545 | GO:0030335 | positive regulation of cell migration | 19525930 | GO:0030838 | positive regulation of actin filament polymerization | 19525930 | GO:0032855 | positive regulation of Rac GTPase activity | 19525930 | GO:0048245 | eosinophil chemotaxis | 10072545 |
| Top |
| Ligand binding site mutations for CCL11 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | K70,I72 | D71N | BRCA | 1 | K67 | K65T | COAD | 1 | K78 | P76S | LAML | 1 | P42 | L43V | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CCL11 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | K78 | P76S | -1.3041791 | K67 | K65T | -0.91035605 | P42 | L43V | -0.65613861 | I72 | D71N | -0.56134919 | K70 | D71N | -0.56134919 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CCL11 from PDB |
| Top |
| Differential gene expression and gene-gene network for CCL11 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CCL11 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0004096 | Asthma | 22 | AlteredExpression, Biomarker, GeneticVariation, Therapeutic |
| umls:C0032285 | Pneumonia | 4 | Biomarker |
| umls:C0021368 | Inflammation | 4 | Biomarker, GeneticVariation |
| umls:C0011615 | Dermatitis, Atopic | 3 | Biomarker, GeneticVariation |
| umls:C0019693 | HIV Infections | 2 | Biomarker, GeneticVariation |
| umls:C0034069 | Pulmonary Fibrosis | 2 | Biomarker |
| umls:C0007786 | Brain Ischemia | 2 | Biomarker, GeneticVariation |
| umls:C0013182 | Drug Hypersensitivity | 1 | Biomarker |
| umls:C0020517 | Hypersensitivity | 1 | Biomarker |
| umls:C0035228 | Respiratory Hypersensitivity | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CCL11 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Investigational | DB05429 | CAT-213 | Biotech |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CCL11 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of CCL11 |
| Multiple alignments for P51671 in multiple species |
| LBS | AA sequence | # species | Species | A37 | CCFNLANRKIP | 1 | Homo sapiens | A37 | CCFIMTSKKIP | 1 | Mus musculus | A37 | CCFTMTSKKIP | 1 | Rattus norvegicus | A37 | CCFNMSKKKIS | 1 | Bos taurus | I41 | MTSKKIPNTLL | 2 | Mus musculus, Rattus norvegicus | I41 | LANRKIPLQRL | 1 | Homo sapiens | I41 | MSKKKISIQRL | 1 | Bos taurus | I72 | KLAKDICADPK | 1 | Homo sapiens | I72 | RLGKEICADPK | 1 | Mus musculus | I72 | KLGKEICADPK | 1 | Rattus norvegicus | I72 | KQNKKICVDPQ | 1 | Bos taurus | K40 | NLANRKIPLQR | 1 | Homo sapiens | K40 | IMTSKKIPNTL | 1 | Mus musculus | K40 | TMTSKKIPNTL | 1 | Rattus norvegicus | K40 | NMSKKKISIQR | 1 | Bos taurus | K67 | VIFKTKLAKDI | 1 | Homo sapiens | K67 | IVFKTRLGKEI | 1 | Mus musculus | K67 | IVFKTKLGKEI | 1 | Rattus norvegicus | K67 | VIFNTKQNKKI | 1 | Bos taurus | K70 | KTKLAKDICAD | 1 | Homo sapiens | K70 | KTRLGKEICAD | 1 | Mus musculus | K70 | KTKLGKEICAD | 1 | Rattus norvegicus | K70 | NTKQNKKICVD | 1 | Bos taurus | K78 | CADPKKKWVQD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K78 | CVDPQEKWVQN | 1 | Bos taurus | L68 | IFKTKLAKDIC | 1 | Homo sapiens | L68 | VFKTRLGKEIC | 1 | Mus musculus | L68 | VFKTKLGKEIC | 1 | Rattus norvegicus | L68 | IFNTKQNKKIC | 1 | Bos taurus | N38 | CFNLANRKIPL | 1 | Homo sapiens | N38 | CFIMTSKKIPN | 1 | Mus musculus | N38 | CFTMTSKKIPN | 1 | Rattus norvegicus | N38 | CFNMSKKKISI | 1 | Bos taurus | P42 | TSKKIPNTLLK | 2 | Mus musculus, Rattus norvegicus | P42 | ANRKIPLQRLE | 1 | Homo sapiens | P42 | SKKKISIQRLQ | 1 | Bos taurus | R39 | FNLANRKIPLQ | 1 | Homo sapiens | R39 | FIMTSKKIPNT | 1 | Mus musculus | R39 | FTMTSKKIPNT | 1 | Rattus norvegicus | R39 | FNMSKKKISIQ | 1 | Bos taurus | R45 | KIPNTLLKSYK | 2 | Mus musculus, Rattus norvegicus | R45 | KIPLQRLESYR | 1 | Homo sapiens | R45 | KISIQRLQSYR | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |